YD BioYDES +23.16%12 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates YDES with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 700 Biotechnology companies, YD Bio ranks better than 61.86% on this metric.
The historical rank and industry rank for YD Bio's Days Payable or its related term are showing as below:
YDES'
s Days Payable Range Over the Past 10 Years
Min: 27.76 Med: 107.25 Max: 186.74
Current: 186.74
During the past 3 years, YD Bio's highest Days Payable was 186.74. The lowest was 27.76. And the median was 107.25.
YDES's Days Payable is ranked better than 61.86% of 700
companies
in the Biotechnology industry
Industry Median: 113.1
vs YDES: 186.74
YD Bio's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
YD Bio Days Payable Related Terms
YD Bio Days Payable Historical Data
* Premium members only.
The historical data trend for YD Bio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YD Bio Days Payable Chart
YD Bio Annual Data
Trend
Dec23
Dec24
Dec25
Days Payable
0.00
27.76
186.74
YD Bio Semi-Annual Data
Dec24
Jun25
Dec25
Days Payable
0.00
0.00
0.00
YDES vs CRBU, ABOS, PRQR: Days Payable Comparison
For the Biotechnology subindustry, YD Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
YD Bio Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, YD Bio's Days Payable distribution charts can be found below:
* The bar in red indicates where YD Bio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
YD Bio's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YD Bio (YDES) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on YD Bio and its competitors. Over the past decade, YD Bio's Days Payable has ranged from 27.76 to 186.74. According to the industry distribution chart, YD Bio ranks #267 out of 700 companies in the Biotechnology industry, placing it in the top 38.1%.
Is YD Bio's Days Payable too high?
YD Bio's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 27.76 to a high of 186.74. Based on the distribution chart, YD Bio ranks #267 out of 700 companies in the Biotechnology industry, which is above the industry midpoint. Overall, YD Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does YD Bio's Days Payable compare to CRBU and ABOS?
According to the Biotechnology industry distribution chart, YD Bio ranks #267 out of 700 companies for Days Payable. This puts YD Bio in the upper half of its industry. The industry median Days Payable is 113.10. Historically, YD Bio's own Days Payable has ranged from 27.76 to 186.74 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on YD Bio and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. YD Bio's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YD Bio stock overvalued right now?
YD Bio (YDES) has a current Days Payable of 0.00. The current Days Payable is 0.00. YD Bio's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For YD Bio (YDES), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
12GF Score
Get the complete analysis for YDES
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YDES has been successfully added to your 